cd7.car/28zeta car t cells
CD7+ Acute Leukemia
Qi dengCell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the CD7+ Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anti-Cd7 Car-T Zhejiang University | Phase 1 | CC |
Same molecule, other indications
cd7.car/28zeta car t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →